Mark Potash

Associate - Boston

Mark Potash
Download Media Photo

Contact Information


  • Boston College Law School, J.D., magna cum laude, Order of the Coif, 2015
  • Boston College, B.S., summa cum laude, Scholar of the College, 2012



Representative Experience

Life Sciences

  • Intellia Therapeutics (Nasdaq: NTLA) in a cross-border collaboration with SparingVision using Intellia’s proprietary CRISPR/Cas9 platform to develop new gene therapies directed to up to three ocular targets, under which Intellia will receive a 10% equity ownership stake in SparingVision, milestone payments of up to approximately $200 million per product, and royalties, as well as an option to US commercialization rights for two of three targets
  • Ginkgo Bioworks (Nasdaq: DNA) in various collaboration and license agreements, including:
    • with Agenus and its subsidiary SaponiQx to develop saponin molecules for high-efficacy and long-lasting protection for pandemic vaccines
    • with Cambium Biomaterials for the development and commercialization of sustainable biomaterials for use in applications across a range of industries
    • with Givaudan to accelerate development and enhance Givaudan's portfolio of taste and scent ingredients
    • with Sumitomo Chemical Co. to significantly increase the production efficiency and sustainability of a key bio-based commercial product
    • with Biogen (Nasdaq: BIIB) to develop a next-generation recombinant adeno-associated virus (AAV) production platform
  • Ginkgo Bioworks, Inc. (Nasdaq: DNA) in the launch of Concentric by Ginkgo, the company’s public health and biosecurity initiative, to provide COVID-19 testing solutions to states, cities and school districts
  • Alloy Therapeutics in multiple matters, including:
    • in the formation of Broadwing Bio LLC, a joint venture with Maze Therapeutics to develop targeted antibody therapies for the treatment of ophthalmic diseases
    • its $75 million Series C financing, led by 8VC, Presight Capital and Peter Thiel
  • Dicerna Pharmaceuticals (Nasdaq: DRNA) in multiple collaboration and license agreements, including:
    • a global collaboration agreement with Novo Nordisk A/S to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases
    • a global collaboration and license agreement in excess of $1.67 billion in upfront and milestone payments, plus royalties, with Roche to develop and commercialize a treatment for chronic Hepatitis B Virus (HBV) infection
    • a global licensing and research collaboration with Eli Lilly focused on potential new medicines in the areas of cardio-metabolic disease, neurodegeneration and pain
    • a collaboration with Alexion Pharmaceuticals to discover and develop RNA interference therapies for complement-mediated diseases
  • Personalized health network PatientsLikeMe in its investment and partnering agreements with digital life company iCarbonX


  • Motional, a global leader in driverless technology, in a landmark agreement with Lyft (Nasdaq: LYFT) to launch a multimarket robotaxi service in major US cities
  • Position Imaging, Inc., a technology company focused on innovations to improve the logistics industry, in a landmark partnership with global technology firm Hitachi-LG Data Storage, Inc.
  • Rental platform Zumper in multiple financing rounds, including:
    • its $60 million Series D round led by
    • its $46 million Series C financing led by Axel Springer and Stereo Capital
    • its $17.6 million Series B funding led by Breyer Capital and Foxhaven Asset Management, including follow-up funding from existing investors
  • Cybersecurity company GreatHorn in multiple transactions, including:
    • a $13 million funding round co-led by RRE Ventures and .406 Ventures
    • its $6.3 million Series A financing led by Techstars Venture Capital Fund and .406 Ventures


  • Boston College Law Review, Articles Editor


  • Boston Bar Association, Member
  • Massachusetts LGBTQ Bar Association, Member
Add to Bio Folder

Download Bio

Bar Admissions

  • Massachusetts